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ABSTRACT
Pseudomonas aeruginosa is one of the leading causes of nosocomial infections. Severe infections, such as
pneumonia or bacteraemia, are associated with high mortality rates and are often difficult to treat, as the
repertoire of useful anti-pseudomonal agents is limited (some b-lactams, fluoroquinolones and
aminoglycosides, and the polymyxins as last-resort drugs); moreover, P. aeruginosa exhibits remarkable
ability to acquire resistance to these agents. Acquired resistance arises by mutation or acquisition of
exogenous resistance determinants and can be mediated by several mechanisms (degrading enzymes,
reduced permeability, active efflux and target modification). Overall, resistance rates are on the increase,
and may be different in different settings, so that surveillance of P. aeruginosa susceptibility is essential
for the definition of empirical regimens. Multidrug resistance is frequent, and clinical isolates resistant to
virtually all anti-pseudomonal agents are increasingly being reported. Monotherapy is usually
recommended for uncomplicated urinary tract infections, while combination therapy is normally
recommended for severe infections, such as bacteraemia and pneumonia, although, at least in some
cases, the advantage of combination therapy remains a matter of debate. Antimicrobial use is a risk
factor for P. aeruginosa resistance, especially with some agents (fluoroquinolones and carbapenems), and
interventions based on antimicrobial rotation and restriction of certain agents can be useful to control the
spread of resistance. Similar measures, together with the prudent use of antibiotics and compliance with
infection control measures, are essential to preserve the efficacy of the currently available anti-
pseudomonal agents, in view of the dearth, in the near future, of new options against multidrug-
resistant P. aeruginosa strains.
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INTRODUCTION
Pseudomonas aeruginosa is a non-fermentative,
aerobic, Gram-negative rod that normally lives
in moist environments. It has minimal nutrition
requirements while being able to use several
organic compounds for growth. This metabolic
versatility contributes to a broad ecological adap-
tability and distribution, and reflects a genome of
larger size and complexity compared with that of
many other bacterial species [1,2].
PSEUDOMONAS AERUGINOSA AS A
PATHOGEN: AN OVERVIEW
Occasionally, P. aeruginosa can colonise human
body sites, with a preference for moist areas, such
as the perineum, axilla, ear, nasal mucosa and
throat; as well as stools. The prevalence of colo-
nisation by P. aeruginosa in healthy subjects is
usually low, but higher colonisation rates can be
encountered following hospitalisation, especially
amongst subjects treated with broad-spectrum
antimicrobial agents. Colonisation is common in
the respiratory tract of mechanically ventilated
patients, in the gastrointestinal tract of patients
receiving anticancer chemotherapy, and on the
skin of burn patients. Also, sinks, mops, disinfect-
ant solutions, respiratory equipment, food mixers
and other moist environments can act as reser-
voirs of P. aeruginosa in the hospital setting [3,4].
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P. aeruginosa is typically an opportunistic patho-
gen that seldom causes disease in healthy subjects.
Normally, for an infection to occur, some disrup-
tion of the physical barriers (skin or mucous
membranes), or by-passing of them (e.g., by
urinary catheters, endotracheal tubes or other
invasive devices), and ⁄ or an underlying dysfunc-
tion of the immune defence mechanisms, such as
neutropenia, is necessary. As a consequence,
P. aeruginosa is mostly a nosocomial pathogen.
According to data from the Centers for Disease
Control and Prevention National Nosocomial
Infection Surveillance System, in the USA,
P. aeruginosa was the second most common cause
of nosocomial pneumonia, the third most common
cause of nosocomial urinary tract infections, and
the seventh most common cause of nosocomial
bacteraemia [5]. In Europe, P. aeruginosawas found
to be the third most common isolate from nosoco-
mial infections in intensive care units (ICUs) [6].
Overall, community-acquired infections by
P. aeruginosa are uncommon. The most frequent
are: (i) folliculitis and infections of the ear canal,
mostly acquired after bathing in contaminated
waters; (ii) cheratitis, usually associated with the
use of a contact lens contaminated during lens
care; (iii) malignant otitis externa with involve-
ment of the underlying tissues and possibly of the
temporal bone and basilar skull, primarily seen in
diabetics and the elderly; (iv) osteomyelitis of the
calcaneus in children, e.g., following puncture
wounds through sneakers whose inner pad is
contaminated by P. aeruginosa; and (v) endocar-
ditis in intravenous drug users, resulting from the
injection of contaminated drug solutions [4,7–11].
The latter is the most severe community-acquired
P. aeruginosa infection, often requiring valve
replacement, and is associated with high mortal-
ity rates [12]. P. aeruginosa is also an uncommon
cause of community-acquired pneumonia, which
may occur in subjects (usually middle-aged and
with a history of smoking) exposed to contamin-
ated aerosolised water. In these cases, patients
rarely receive appropriate empirical chemother-
apy and mortality can be high [13].
Nosocomial infections caused by P. aeruginosa
most frequently involve the respiratory tract, the
urinary tract and wounds. P. aeruginosa is
amongst the leading causes of nosocomial pneu-
monia, especially in mechanically ventilated
patients. Overall, these patients have a much
higher probability of developing nosocomial
pneumonia, with P. aeruginosa being the most
frequent cause. Mortality rates ranging from 40%
to more than 60% have been reported in bacter-
aemic nosocomial pneumonia and in ventilator-
associated pneumonia [14–16]. Nosocomial
urinary tract infections caused by P. aeruginosa
are usually related to catheterisation or other
invasive procedures, and may be complicated by
bacteraemia [4]. According to surveillance data,
P. aeruginosawas the third and fifth most common
cause of hospital-acquired urinary tract infections
in the USA and Europe, respectively [17,18].
Wound infections are particularly serious in burn
patients, where they are often complicated by
bacteraemia [19]. P. aeruginosa bacteraemia and
septic shock are primarily observed in immuno-
compromised patients, and are associated with
high mortality rates (from one-third to almost
two-thirds of cases) [20–23]. All situations associ-
ated with severe neutropenia and mucosal ulcer-
ations, such as haematological malignancies,
cancer chemotherapy and organ transplantation,
create a significant risk for the development of
P. aeruginosa bacteraemia [4,24–27]. Other predis-
posing factors include diabetes mellitus, immu-
noglobulin deficiency states, severe burns, steroid
therapy, surgery and the use of invasive devices
[4]. In cancer patients, P. aeruginosa can be
responsible for up to 30% of culture-proven cases
of bacteraemia, with mortality rates ranging from
5% to 50% [28]. In a recent surveillance study on
nosocomial bloodstream isolates carried out in the
Americas, P. aeruginosa was found to be the third
most common pathogen [29]. P. aeruginosa can
also cause peritonitis in patients on chronic
ambulatory peritoneal dialysis [30].
P. aeruginosa is a major pathogen in cystic
fibrosis patients, most of whom, sooner or later,
develop respiratory tract infection with P. aerugi-
nosa which typically exhibits a mucoid pheno-
type. The abnormal airway epithelia of these
patients allow long-term colonisation by P. aeru-
ginosa and, once infected, they rarely, if ever, clear
the microorganism, which, in turn, plays a critical
role in the progression of lung disease [4,31].
Finally, P. aeruginosa can be an important cause
of morbidity and mortality in both paediatric and
adult patients with acquired immunodeficiency
syndrome with very low CD4 counts [32–34], a
condition that altogether has become less frequent
since the introduction of highly active anti-retro-
viral regimens.
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The virulence mechanisms of P. aeruginosa
are complex and only partially understood.
Adherence mediated by pili and other adhesins
appears to be important for the colonisation of
mucous membranes and other surfaces [35–37],
while the production of a mucoid exopolysaccha-
ride matrix that surrounds the cells and anchors
them to each other and to the environment is
important for growth as a biofilm, in which the
bacterial cells are protected from the host innate
and immune defences and are overall less sus-
ceptible to antibiotics [38–41]. A role for tissue
damage and invasion has been recognised for a
number of products secreted by P. aeruginosa,
including elastase, alkaline protease, cytotoxin,
phospholipase C and rhamnolipid [42–46]. Final-
ly, local and systemic toxicity is most probably
related to endotoxin release, and to the produc-
tion of exotoxin A (an extracellular enzyme that
inhibits mammalian protein synthesis) and exo-
enzyme S (which can ADP-ribosylate several
GTP-binding proteins) [47–51]. The production
of exoenzymes and other virulence factors is
controlled by a quorum-sensing regulatory mech-
anism that leads to a coordinate expression of the
corresponding genes only when the microbial cell
density exceeds certain values. This mechanism
allows the production of virulence factors only
when there is a reasonable chance that the
infection may overcome the host defences, and
thus reduces the possibility of immunisation
against these products which may be detrimental
to the bacterium [52]. Indeed, functional quorum-
sensing systems are important for P. aeruginosa
virulence, although quorum-sensing mutants are
not avirulent, revealing that pathogenesis is also
regulated by other factors [53–55].
The laboratory diagnosis of infection is usually
simple, as P. aeruginosa grows on most routine
culture media and is easily identified by com-
mercial identification systems for Gram-negative
pathogens [56]. Recovery of P. aeruginosa from
normally sterile sites is always considered to be
clinically significant, while recovery from non-
sterile sites is only considered to be significant
when associated with a typical clinical syndrome
(e.g., otitis externa). In the case of intubated
patients, it is particularly important to discrimin-
ate between colonisation and infection as, in
the latter case, the mortality rates are high
and aggressive antimicrobial chemotherapy is
required. In these cases, the presence of large
amounts of Gram-negative bacilli and polymor-
phonuclear leucocytes in Gram-stained secretions
obtained by endotracheal suction is suggestive of
a diagnosis of nosocomial pneumonia [57].
THE ANTI-PSEUDOMONAL DRUGS
AND ACQUIRED ANTIMICROBIAL
RESISTANCE IN P. AERUGINOSA
P. aeruginosa is intrinsically resistant to many
antimicrobial agents, including most b-lactams,
the older quinolones, chloramphenicol, tetracyc-
line, macrolides, trimethoprim–sulfamethoxazole
and rifampin.
The AmpC chromosomal b-lactamase, the pro-
duction of which is inducible, contributes to the
intrinsic resistance of this species to ampicillin
and to most cephems, which act as inducers and
are degraded by this enzyme [58]. An overall low
permeability of the outer membrane and the
presence of a number of active multidrug efflux
systems also contribute to the intrinsic resistance
or reduced susceptibility of this species to several
antimicrobial agents [59,60]. For instance, the
three-component MexA–MexB–OprM, MexC–
MexD–OprJ, MexE–MexF–OprN and MexX–
MexY–OprM systems can extrude a wide variety
of antimicrobial agents (including quinolones,
tetracycline, chloramphenicol, macrolides, sul-
phonamides, trimethoprim, aminoglycosides and
most b-lactams) and, with their basal activity,
provide an important defence against these drugs,
as demonstrated by the increased susceptibility to
the various agents exhibited by knock-out
mutants for these systems [61–64]. The aminogly-
cosides can also be actively extruded, in
P. aeruginosa, by the MexX–MexY linker-pump
module in combination with different outer
membrane channels (OpmG and OpmI) [65].
As a consequence, the repertoire of antimicro-
bial agents that can be used against P. aeruginosa
infections is relatively limited. Themost important
anti-pseudomonal agents include some b-lactams
(ticarcillin, ureidopenicillins, piperacillin, cefoper-
azone, ceftazidime, cefepime, aztreonam, imipe-
nem and meropenem), aminoglycosides
(gentamicin, tobramycin, netilmicin and amika-
cin) and fluoroquinolones (of which ciprofloxacin
remains the most active compound) [66,67].
Polymyxins (polymyxin B and colistin) are also
active but, due to their higher toxicity, are usually
considered only for multidrug-resistant (MDR)
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strains that are resistant to the other agents [68].
Concerning the b-lactam–b-lactamase inhibitor
combinations, piperacillin–tazobactam is prefer-
able to ticarcillin–clavulanate for the treatment
of P. aeruginosa infections because of the more
favourable pharmacokinetics of tazobactam, the
superior anti-pseudomonal activity of piperacillin,
and the fact that, unlike tazobactam, clavulanate
usually induces the production of the P. aeruginosa
AmpC enzyme and could antagonise the anti-
microbial activity of ticarcillin [69,70].
Acquired resistance to any of the anti-pseudo-
monal agents is possible and has been described.
Resistance to anti-pseudomonal b-lactams is
common and can result from one or more of
several different mechanisms (Table 1). Mutations
leading to the increased production of the AmpC
b-lactamase can occur at frequencies of 10)7)10)9,
and may result in decreased susceptibility to
overt resistance (depending on the amount of
enzyme, mutant phenotype and b-lactam com-
pound) to those compounds that are normally
active as they do not induce AmpC production,
but that are not entirely stable to the enzyme
(penicillins, cephems and monobactams) [58].
Three different mutant phenotypes have been
described, including a moderate-level constitutive
production, a high-level constitutive production
and a moderate-level basal with hyperinducible
production [71,72]. The mutational events leading
to the deregulation of AmpC production in
P. aeruginosa have been identified only in part
[73,74], but they appear to be substantially differ-
ent from those usually responsible for the same
phenomenon in Enterobacteriaceae. Moreover, in
P. aeruginosa, multiple mutational pathways could
be responsible for these phenotypes [74], which
would explain the phenotype heterogeneity and
notable tendency to segregate similar mutants.
Mutations leading to a decreased amount of the
OprD porin can occur at relatively high frequency
(10)7) and result in resistance to imipenem and
reduced susceptibility to meropenem [75,76]. Loss
of OprD production can be due to deletions,
substitutions or insertions that cause inactivation
of the oprD gene [77,78], but OprD production can
Table 1. Acquired resistance mech-
anisms to anti-pseudomonal agents
Resistance mechanism Affected anti-pseudomonal agents
Acquired by mutation
AmpC derepression Penicillins, cephems, monobactamsa
OprD loss Carbapenems
Up-regulation of efflux pumps
MexA–MexB–OprM All b-lactams except imipenem
Fluoroquinolones
MexC–MexD–OprJ Some b-lactams (cefoperazone,
cefpirome, cefepime, meropenem)
Fluoroquinolones
MexE–MexF–OprN Fluoroquinolones
(Carbapenems)b
MexX–MexY–OprM Some b-lactams
(cefoperazone cefpirome, cefepime, meropenem)
Fluoroquinolones
Aminoglycosides
GyrA and ⁄ or ParC modification Fluoroquinolones
Membrane changes Polymyxins, aminoglycosides
Acquired following transfer of exogenous resistance genes
b-Lactamases
Narrow-spectrum molecular class A
(e.g., PSE-1, PSE-4, TEM-1)and class D (e.g., OXA-3)
enzymes
Penicillins, cefoperazone
Extended-spectrum molecular class A (e.g., PER-1,
VEB-1, GES-1, GES-2,TEM-42, SHV-5) and class D
(e.g., OXA-11, OXA-14, OXA-18, OXA-28) enzymes
Penicillins, cephems, monobactamsc
Molecular class B metallo-enzymes
(IMP-, VIM-, SPM- and GIM-type enzymes)
All b-lactams except monobactams
Aminoglycoside-modifying enzymesd
AAC(3)-I Gentamicin
AAC(3)-II Gentamicin, tobramycin, netilmicin
AAC(6¢)-I Tobramycin, netilmicin, amikacin
AAC(6¢)-II Gentamicin, tobramycin, netilmicin
ANT(2¢)-I Gentamicin, tobramycin
aThe effect of AmpC derepression on susceptibility is lower with some compounds that are poorly hydrolysed by
the enzyme (e.g., carbenicillin and cefepime).
bIn this case, decreased susceptibility to carbapenems is dependent on the concomitant OprD decrease observed in
these mutants.
cSubstrate profiles can be somewhat different for different enzymes. For instance, PER-1 exhibits poor activity
against piperacillin. GES-2 also exhibits a modest carbapenemase activity that can confer resistance to imipenem
when associated with permeability defects.
dOther modification enzymes can also be found, although rarely, in Pseudomonas aeruginosa.
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also decrease following regulatory mutations that
cause both the down-regulation of OprD and the
up-regulation of the MexE–MexF–OprN efflux
system [62,79]. In the former case, only suscepti-
bility to imipenem is affected, while, in the latter
case, susceptibility to quinolones is also decreased
[62]. Mutations leading to the up-regulation of
efflux systems (MexA–MexB–OprM, MexC–
MexD–OprJ, MexE–MexF–OprN and MexX–
MexY–OprM) can variably result in decreased
susceptibility to full resistance (depending on the
system, the level of up-regulation and the com-
pound) to anti-pseudomonal b-lactams. Up-regu-
lation of the MexA–MexB–OprM system, which is
usually caused by mutations that inactivate the
mexR regulatory gene [80–82], decreases suscep-
tibility to virtually all anti-pseudomonal b-lac-
tams, except imipenem [64,80,82], while
up-regulation of the MexC–MexD–OprJ and
MexX–MexY–OprM systems only affects suscep-
tibility to some cephems (cefpirome, cefepime,
cefoperazone) and to meropenem [64]. On the
other hand, the MexE–MexF–OprN system does
not efflux b-lactams, but the up-regulation of this
system indirectly affects carbapenem susceptibil-
ity due to concomitant down-regulation of OprD
[62,79]. Finally, the acquisition of secondary
b-lactamase genes by horizontal transfer can be
responsible for acquired b-lactam resistance, the
spectrum of which reflects the substrate specific-
ity of the acquired enzyme. From this point of
view, the acquired b-lactamases found in
P. aeruginosa can belong to three different groups:
(i) narrow-spectrum active site-serine enzymes of
molecular classes A and D (e.g., PSE-1, PSE-4 and
some OXA-type enzymes) that efficiently degrade
the anti-pseudomonal penicillins and cefopera-
zone, but have no significant activity against the
other anti-pseudomonal cephems, monobactams
or carbapenems [58,83,84]; (ii) extended-spectrum
active site-serine enzymes of molecular classes A
and D (e.g., PER-1, VEB-1, GES-1, GES-2, various
OXA-type enzymes and, although rarely, also
TEM- and SHV-type extended-spectrum variants)
that, in addition to penicillins, can also degrade
the anti-pseudomonal cephems and monobac-
tams but not carbapenems [58,83,85–87] (the
GES-2 enzyme also has a modest carbapenemase
activity that can confer resistance to imipenem
when associated with impermeability-mediated
resistance mechanisms [88]); and (iii) metallo-
enzymes of molecular class B (e.g., the enzymes of
the IMP, VIM, SPM and GIM type) that efficiently
degrade virtually all the anti-pseudomonal
b-lactams except monobactams [89–93]. Members
of the last two groups are the most worrisome
from the clinical standpoint due to their broad
substrate profiles; and although, in most cases,
isolates producing these are still found sporadic-
ally or may cause small outbreaks, similar
enzymes are progressively disseminating in the
clinical setting and are currently included
amongst the emerging b-lactamases of increasing
clinical importance [90,94–96]. In some cases,
multiple acquired b-lactamases can be found
in clinical isolates, broadening the spectrum of
b-lactam resistance. In particular, the simulta-
neous presence of an extended-spectrum b-lacta-
mase and a metallo-b-lactamase can result in a
phenotype of resistance to all the anti-pseudomo-
nal b-lactams [97].
Acquired resistance to aminoglycosides can be
due to the production of aminoglycoside-modify-
ing enzymes encoded by horizontally acquired
resistance determinants, or by mutations that
reduce aminoglycoside accumulation in the bac-
terial cell [98] (Table 1). The most prevalent
aminoglycoside-modifying enzymes found in
P. aeruginosa are the acetyl-transferases AAC(6¢)-
II (resistance to gentamicin, tobramycin and
netilmicin), AAC(3)-I (resistance to gentamicin),
AAC(3)-II (resistance to gentamicin, tobramycin
and netilmicin) and AAC(6¢)-I (resistance to
tobramycin, netilmicin and amikacin), and the
adenylyl-transferase ANT(2¢)-I (resistance to gen-
tamicin and tobramycin) [99,100]. Reduced ami-
noglycoside uptake could be due to mutations
causing lipopolysaccharide changes [101] or
up-regulation of efflux systems based on the
MexX–MexY linker-pump module [64,65]. Unlike
resistance mediated by modifying enzymes, the
spectrum of which can be variable depending on
the nature of the enzyme, resistance mediated by
efflux systems tends to be broad spectrum [64,65].
Acquired resistance to fluoroquinolones can be
due either to mutations that cause the up-regula-
tion of efflux systems, including MexA–MexB–
OprM, MexC–MexD–OprJ, MexE–MexF–OprN
and MexX–MexY–OprM [60 and references there-
in], or to mutations of the topoisomerase targets
(gyrA and also parC) [102,103] (Table 1). Both
mechanisms are responsible for cross-resistance
to all fluoroquinolones, and none of the new
fluoroquinolones retains activity against cipro-
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floxacin-resistant isolates [104]. Efflux mutants
also typically exhibit a decreased susceptibility to
other drugs, while only quinolone susceptibility is
affected in target mutants. Efflux and target
mutations can cooperate to increase the resistance
level [105]. The multiple mutational events that
can be responsible for quinolone resistance
account for the relatively high frequency at which
these drugs can select for resistant isolates.
Finally, acquired resistance to polymyxins has
been occasionally described in P. aeruginosa iso-
lates from cystic fibrosis patients treated for long
periods with the nebulised drug, and seems to be
related to mutations causing changes in the outer
membrane structure [106].
Different mechanisms can cooperate to increase
the resistance level to certain antimicrobial agents.
For instance, loss of OprD and up-regulation of
the MexAB–OprM efflux system can cooperate to
increase the level of resistance to meropenem [76],
while the loss of OprD and constitutive high-level
production of the AmpC enzyme can cooperate to
increase the level of resistance to imipenem, as the
enzyme has a very modest activity against imi-
penem that can become significant when the
permeability rate is reduced [107].
Mutational resistance can emerge during anti-
microbial chemotherapy and result in therapeutic
failures. This phenomenon is associated with an
increase in morbidity and mortality, length of
hospital stay and total hospital costs [108]. Emer-
gence of resistance during therapy can be more
frequent with some antimicrobial agents. For
instance, a 17% rate of resistance emerging
during imipenem treatment of P. aeruginosa
infections has been reported [109], and controlled
studies comparing imipenem with ceftazidime,
piperacillin–tazobactam or ciprofloxacin, for the
treatment of P. aeruginosa pneumonia, showed
that imipenem was less effective than compara-
tors because of the ease with which P. aeruginosa
becomes resistant to this carbapenem during
therapy [110–112].
Although the simultaneous emergence of mul-
tiple mutants is highly unlikely, sequential emer-
gence is possible and is facilitated by the fact that
infections caused by a strain resistant to certain
antibiotics are thus treated with a different anti-
biotic [106]. Moreover, in some cases, a single
mutational event can compromise multiple drugs
with different mechanisms (e.g., mutations lead-
ing to the up-regulation of efflux systems that
cause resistance to both fluoroquinolones and
b-lactams). On the other hand, acquired resistance
genes are often carried on genetic elements (such
as plasmids, transposons or integrons) in which
several resistance determinants are clustered, so
that an MDR phenotype can be acquired in a
single step upon acquisition of the element [113–
116]. All of this accounts for the remarkable
potential of P. aeruginosa to evolve rapidly
towards multidrug resistance.
ANTIMICROBIAL SUSCEPTIBILITY
AND RESISTANCE TRENDS
Surveillance of the antimicrobial susceptibility of
P. aeruginosa clinical isolates has been monitored
in various large-scale multicentric longitudinal
studies, e.g., SENTRY antimicrobial surveillance
programme (http://www.ewi.med.uu.nl/enare/
sentry_antimicrobial_resistance_about.html), MYS-
TIC programme (http://www.mystic-info.com/
media/default.asp) and Intensive Care Antimi-
crobial Resistance Epidemiology (ICARE) project
[117], as well as in a large number of smaller scale
surveys [118–123, and references therein]. Sur-
veillance of P. aeruginosa susceptibility is partic-
ularly important because of the large number of
cases in which antimicrobial chemotherapy must
be initiated empirically, and to the higher failure
rates when the pathogen proves to be resistant to
the agents prescribed empirically [124].
All surveillance studies reveal that there is no
single drug active against 100% of P. aeruginosa
clinical isolates (polymyxins are usually not tes-
ted). According to recent data from the largest
multicentric surveillance study [125], amikacin,
piperacillin–tazobactam and carbapenems remain
the most active drugs worldwide, while ticarcillin
and aztreonam show the lowest activities
(Table 2). Susceptibility rates indicate significant
geographical differences: overall, the highest rates
are observed in North America and the Asia-
Pacific region, while the lowest rates are observed
in Latin America, with Europe being in an
intermediate position (Table 2). In the case of
some drugs, regional differences slightly overrule
this general pattern: for instance, the fluoroqui-
nolones retain a significantly better activity in the
Asia-Pacific region compared with North Amer-
ica, whereas aztreonam retains a better activity in
Europe in comparison with other areas (Table 2).
Differences in susceptibility rates can also be
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observed on a smaller scale among different
countries [118–122,126]. When comparing data
from surveillance studies, however, it should also
be considered that, in some cases, different
breakpoints are used, which partially accounts
for some differences.
In ICUs, where P. aeruginosa is one of the
leading causes of severe nosocomial infections,
susceptibility rates tend to be lower than in
general wards for some b-lactams (carbapenems,
ceftazidime, ticarcillin–clavulanate) and, in Eur-
ope, also for ciprofloxacin and gentamicin, while
remarkable differences are not observed with
other drugs, such as piperacillin–tazobactam,
cefepime and amikacin [123,127]. A comparative
analysis of recent data concerning ICU isolates
confirmed that, overall, higher resistance rates are
observed in Europe compared with the USA; it
also revealed a great diversity of resistance rates
for different drugs in different European settings
and at different times (Table 3). Similar findings
probably reflect the variability in drug prescrip-
tion policies, as well as the circulation of different
P. aeruginosa strains in different settings, and
underscore the notion that data from local sur-
veillance programmes are essential in determin-
ing the most appropriate guidelines for empirical
regimens in individual hospital settings.
Concerning resistance trends, data from large-
scale surveillance studies indicate, overall, an
increasing trend during the past few years,
although with notable differences for different
drugs and geographical areas. This trend is
particularly evident for fluoroquinolones, for
which resistance appears to be increasing at a
higher rate than for other antimicrobial agents in
the USA, Europe and Latin America. Concerning
aminoglycosides, a trend of increasing resistance
is evident in Europe and in Latin America, but not
in the USA. Concerning b-lactams, a trend of
increasing resistance to all anti-pseudomonal
b-lactams is evident in Europe, but is less marked
in Latin America (where ceftazidime and cefep-
ime appear to be spared) and for North America
(where increases in the resistance rates for various
b-lactams tend to be marginal and sometimes
unconfirmed [122,123,129,130].
Multidrug resistance can be relatively common
amongst nosocomial isolates of P. aeruginosa,
which represent the large majority of clinical
isolates. In the SENTRY surveillance programme,
the rates of multidrug resistance (defined as being
resistant to piperacillin, ceftazidime, imipenem
and gentamicin) were found to reflect geograph-
ical differences, being higher in Latin America
(c. 8%), lower in Europe (c. 5%) and even lower in
North America and the Asia-Pacific region (< 2%)
[130]. Higher multidrug resistance rates are
observed in ICUs [123], probably because of the
tendency for MDR strains to cause outbreaks in
Table 2. Antimicrobial susceptibility rates (%) of Pseudo-
monas aeruginosa clinical isolates from different areas. Data
are from the SENTRY antimicrobial surveillance pro-
gramme [125]
Agent Europe
North
America
Latin
America Asia-Pacific
Amikacin 86 95 73 95
Tobramycin 76 92 66 90
Gentamicin 72 84 62 84
Piperacillin 80 87 68 86
Piperacillin–
tazobactam
86 90 77 89
Ticarcillin 74 78 58 76
Ticarcillin–
clavulanate
78 78 59 75
Ceftazidime 80 80 66 79
Cefepime 80 83 67 83
Aztreonam 73 66 49 67
Imipenem 82 87 76 88
Meropenem 85 91 80 90
Ciprofloxacin 72 78 63 85
Table 3. Antimicrobial resistance
rates (%) of Pseudomonas aeruginosa
clinical isolates from intensive care
units (ICUs). Numbers are the rates
of intermediately resistant and
resistant isolates. Data were derived
from Karlowsky et al. [123] and
Hanberger et al. [128]
Agent
Various EU
countries
(1990–97)a
Europe
(1997–98)
Europe
(1999)
USA
(1997–99)
USA
(1998–2001)
Amikacin 4–37 13 30 3 7
Gentamicin 7–70 26 44 15 23
Piperacillin–
tazobactam
5–53 15 36 12 9
Ceftazidime 11–57 19 29 24 17
Cefepime 3–57 17 32 19 19
Imipenem 10–52 22 38 15 20
Meropenem n.a.b 16 34 n.a. 21
Ciprofloxacin 8–56 27 40 20 24
aIncluding Belgium (1990 and 1994–95), Holland (1990), Germany (1990), France (1991 and 1994–95), Portugal
(1994–95), Spain (1994–95), Sweden (1994–95 and 1997) and Turkey (1997).
bn.a., data not available.
Rossolini and Mantengoli Multiresistant Pseudomonas aeruginosa 23
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11 (Suppl. 4), 17–32
such settings. An increasing trend has also been
reported for multidrug resistance rates in recent
years [106,123]. For instance, the prevalence of
MDR isolates (resistant to at least three of six
drugs, including amikacin, gentamicin, ciprofl-
oxacin, piperacillin, ceftazidime and imipenem)
has increased from 13% in 1997 to 21% in 2000,
according to surveillance data from the USA
[106].
Isolates that exhibit resistance to virtually all
available anti-pseudomonal agents (polymyxins
are rarely tested in the clinical laboratory) are
increasingly being reported [97,106,130–134]. The
appearance of similar ‘panresistant’ isolates is one
of the most worrisome developments in the
context of microbial drug resistance, recreating
conditions typical of the pre-antibiotic era, and
has resulted in the search for anti-pseudomonal
agents with alternative mechanisms of action and
in the use of polymyxins despite their toxicity
[68,135,136].
Continuous surveillance of susceptibility data
in nosocomial institutions is of paramount import-
ance, not only for the determination of guidelines
for empirical regimens, but also for prompt
enforcement of infection control measures. The
appearance of multiple P. aeruginosa isolates with
an unusual susceptibility pattern should immedi-
ately alert those responsible for the infection
control system to the possibility of a nosocomial
outbreak due to an MDR strain, and should thus
lead to specific control measures [137].
TREATMENT OF SEVERE
INFECTIONS CAUSED BY MDR
P. AERUGINOSA
In-vitro susceptibility data are essential support
for the selection of antimicrobial chemotherapy
for P. aeruginosa infections, because of the fre-
quency and variability of acquired resistance
shown by clinical isolates. Susceptibility testing
is well standardised for most anti-pseudomonal
agents, but there are no recommended break-
points for susceptibility testing of polymyxin B or
colistin [56]. MIC determination is preferable in
the case of these drugs because the correlation
with disk diffusion testing is relatively poor [138].
As P. aeruginosa can be a lethal pathogen and
the precocity of chemotherapy is critical to the
outcome of the infection, empirical regimens
adequate for P. aeruginosa coverage should always
be initiated prior to receipt of the results of
cultures and susceptibility testing when infection
by this species is suspected. For the selection of
empirical regimens, several aspects should be
considered, including: (i) the nature and source
(nosocomial vs. community-acquired) of the
infection; (ii) information concerning the epidemi-
ology of resistance phenotypes in the individual
setting; (iii) pharmacokinetic parameters; (iv)
underlying risk factors (e.g., length of hospitali-
sation, ICU admissions, previous antimicrobial
chemotherapy) and diseases; and (v) hospital
prescription policies.
Antibiotic monotherapy is usually recommen-
ded for urinary tract infections caused by
P. aeruginosa, with the exception of upper tract
infections complicated by abscess formation, or
for infections in neutropenic patients, or when-
ever there is a suspicion of bacteraemia. On the
other hand, combination chemotherapy with at
least two different anti-pseudomonal agents is
normally recommended for the treatment of
severe P. aeruginosa infections, such as endocar-
ditis, nosocomial pneumonia and bacteraemia [4].
The rationale for combination chemotherapy is
essentially to reduce the chances of selection of
resistant mutants during therapy, as well as to
exploit the potential synergistic activity of some
agents. The preferred combination remains ami-
noglycosides and b-lactams, as synergism be-
tween these drugs has been demonstrated by in-
vitro studies [139–141], and results of several
clinical studies point to the superiority of similar
regimens as opposed to monotherapy for the
treatment of P. aeruginosa bacteraemia, especially
in neutropenic patients [20,142–144]. However,
some clinical studies have cast doubt on the actual
superiority of combination chemotherapy, at least
in some cases [22,68,145,146]. These apparently
conflicting results probably reflect the complexity
of variables that come into play in similar studies.
It has also been argued that the absence of
demonstrated superiority of combination therapy
over monotherapy demonstrated in some studies
may be due to the fact that the combinations were
not synergistic against the pathogen [147]. Indeed,
the superiority of combinations that exhibit sy-
nergistic activity in vitro as opposed to non-
synergistic combinations has been reported in
some studies [143,148,149]. Whilst waiting for the
results of large prospective randomised trials
comparing monotherapy and combination drug
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therapy for serious nosocomial P. aeruginosa
infections, most physicians continue to prefer
combination therapy for treatment; combination
chemotherapy, although not showing an unequi-
vocally superior effect to monotherapy, has never
been shown to be inferior [4,150].
Concerning the empirical treatment of febrile
neutropenic patients, where P. aeruginosa can be a
causative agent, therapeutic regimens, as well as
the use of single vs. combination chemotherapy,
have been a matter of continued debate. Several
studies point to a comparable efficacy of mono-
therapy with broad-spectrum b-lactams com-
pared with the combination of these drugs and
an aminoglycoside [151–157]. However, they also
underscore the importance of a careful considera-
tion of local epidemiological data in selection of
the therapeutic regimen [155,157]. Indeed, when
surveillance data reveal a notable level of resist-
ance in P. aeruginosa, empirical regimens for
P. aeruginosa coverage might require the initial
use of two or more agents [130]. Some authors still
recommend that, when P. aeruginosa bacteraemia
is strongly suspected on the basis of clinical
setting or local epidemiology, combination ther-
apy should be instituted with an aminoglycoside
and a b-lactam with dependable anti-pseudomo-
nal activity, and, if P. aeruginosa bacteraemia is
subsequently documented, a similar combination
regimen should be initiated even if the patient has
already responded to monotherapy [4].
In cystic fibrosis patients, early aggressive
combination chemotherapy is currently recom-
mended for initial colonisation episodes, to delay
as long as possible the onset of chronic
P. aeruginosa infection, whilst maintenance che-
motherapy based on the administration of anti-
pseudomonal agents at regular intervals can
significantly improve the survival of these
patients once they have developed chronic
P. aeruginosa infections [158–160].
FACTORS INFLUENCING ACQUIRED
RESISTANCE
Several factors indicate that the emergence and
spreadof drug-resistantP. aeruginosa can be related
to the overuse of antimicrobial agents, although the
risk appears to differ with different agents.
A strong association between use and resist-
ance has been documented for carbapenems. A
significant increase in the incidence of imipenem-
resistant P. aeruginosa was observed at a large
New York medical centre following an interven-
tion that restricted the use of cephalosporins (in
order to control the spread of ceftazidime-resist-
ant Klebsiella pneumoniae) and caused, at the same
time, an increased imipenem consumption [161].
A strong association between imipenem use and
resistance in P. aeruginosa was also observed in a
3-year survey of antimicrobial consumption and
resistance carried out in a German hospital [162].
In that study, imipenem consumption was found
to be significantly associated with imipenem
resistance rates and also with ceftazidime and
piperacillin–tazobactam resistance rates from the
same month and from the following month. By
contrast, no correlation was observed between the
consumption of ceftazidime or piperacillin–tazo-
bactam and resistance to the same drugs or to
imipenem. Finally, in a cohort study comparing
the relative risks for the emergence of resistant
P. aeruginosa in patients treated with different
anti-pseudomonal agents, imipenem was found
to be associated with a significantly higher overall
risk of emergence of resistance, and exhibited the
highest risk of emergence of resistance to itself.
On the other hand, ceftazidime had the lowest
overall risk for the emergence of resistance and
showed no significant association with the emer-
gence of resistance to itself. Piperacillin and
ciprofloxacin showed a low overall risk for emer-
gence of resistance, but were distinctly associated
with the emergence of resistance to themselves
[108].
Several case–control studies carried out
amongst hospitalised patients point to the role
of antimicrobial agents, in addition to other
variables (such as ICU stay and length of hos-
pitalisation), as risk factors for drug-resistant
P. aeruginosa. In particular, following multivaria-
ble analysis, fluoroquinolones were identified as
risk factors for piperacillin-resistant P. aeruginosa
in ventilator-associated pneumonia [163], while
imipenem, piperacillin–tazobactam and amino-
glycosides were identified as risk factors for
imipenem-resistant P. aeruginosa [164]; the same
drugs plus extended-spectrum cephalosporins
were identified as risk factors for piperacillin–
tazobactam-resistant P. aeruginosa [165].
The effect of antimicrobial restriction on
P. aeruginosa resistance has been investigated in
a recently published study carried out in a large
teaching hospital [166]. In that study, the inter-
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vention caused a remarkable reduction in the use
of ceftazidime and a consistent reduction in the
use of imipenem, and was associated with a
significant decrease in the resistance rates to these
two drugs. Interestingly, a significant decrease in
resistance rates was also observed for piperacillin
and aztreonam, notwithstanding minimal chan-
ges in the overall use of piperacillin and pipera-
cillin–tazobactam and a consistent increase in the
use of aztreonam. In another prospective study,
carried out in a medical ICU in another large
teaching hospital, ceftazidime and ciprofloxacin
restriction, in combination with an antimicrobial
rotation strategy, was shown to be effective in
reducing the overall incidence of ventilator-asso-
ciated pneumonia and the resistance rates of
P. aeruginosa to various antimicrobial agents,
including extended-spectrum cephalosporins,
aminoglycosides and fluoroquinolones [167].
Formulary interventions aimed at the prudent
use of certain drugs may therefore be beneficial
for the control of the antimicrobial resistance of
P. aeruginosa in hospital settings, similar to the
observations made for other resistant pathogens
[168,169]. There is also a need to underscore the
importance of strict compliance with recommen-
ded infection control practices to limit the spread
of MDR P. aeruginosa clones within the hospital
environment [170,171].
CONCLUSION
P. aeruginosa remains one of the most important
and difficult to treat nosocomial pathogens. MDR
strains are increasingly being reported and, in
these cases, the choice of therapy often becomes
very limited, especially when looking for antimi-
crobial combinations to treat severe infections. An
additional matter of concern is represented by the
fact that no new antimicrobial agents, active
against MDR strains of P. aeruginosa, are in
advanced stages of development as therapeutic
options. The development of clinafloxacin, a fluor-
oquinolone that is slightly more active than cipro-
floxacin against P. aeruginosa [172], has been
suspended. Inhibitors of multidrug efflux systems
[173] and new b-lactamase inhibitors that are
highly active against AmpC and ⁄ or the metallo-
enzymes [174,175] are the subject of intensive
investigation, and could become valuable tools
to rescue the activity of fluoroquinolones and
b-lactams against resistant strains, as well as to
broaden the repertoire of useful anti-pseudomonal
drugs. Also promising is the development of new
antibacterial peptides that disrupt the bacterial
lipopolysaccharide, and may be especially useful
for topical application against MDR isolates [176–
178].
While the medical community awaits the
development of new drugs, MDR P. aeruginosa
strains are likely to represent an increasing threat,
and every effort should be made to preserve as
long as possible, or to restore, the efficacy of
currently available agents.
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